TY - JOUR
T1 - Low risk of thromboembolic complications with tranexamic acid after primary total hip and knee arthroplasty knee
AU - Gillette, Blake P.
AU - Desimone, Lori J.
AU - Trousdale, Robert T.
AU - Pagnano, Mark W.
AU - Sierra, Rafael J.
N1 - Funding Information:
One of the authors (RTT) certifies that he, or a member of his immediate family, has received or may receive payments or benefits, during the study period, an amount in excess of $100,000 from DePuy Orthopaedics, Inc (Warsaw, IN, USA), Wright Medical Technology, Inc (Arlington, TN, USA), MAKO Surgical Corp (Ft Lauderdale, FL, USA), and Ortho Development Corp (Draper, UT, USA). One or more of the authors (MWP) certifies that he, or a member of his immediate family, has received or may receive payments or benefits, during the study period, an amount in excess of $100,000 from DePuy, MAKO Surgical Corp, and Stryker Orthopaedics (Mahwah, NJ, USA). One of the authors (RJS) certifies that he, or a member of his immediate family, has received or may receive payments or benefits, during the study period, an amount in excess of $10,000 from Biomet Inc (Warsaw, IN, USA) and Arthrex Inc (Naples, FL, USA). The institution of one of the authors (RTT) has received research support, during the study period, from Zimmer, Inc (Warsaw, IN, USA). The institution of one of the authors (RJS) has received research support, during the study period, from DePuy, Zimmer, and Stryker (RJS). The remaining authors certify that they, or a member of their immediate family, have no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article. The project described was supported by Grant Number 1 UL1 RR024150-01 from the National Center for Research Resources (NCRR), a component of the NIH, and the NIH Roadmap for Medical
PY - 2013/1
Y1 - 2013/1
N2 - Background: The use of antifibrinolytic medications in hip and knee arthroplasty reduces intraoperative blood loss and decreases transfusion rates postoperatively. Tranexamic acid (TXA) specifically has not been associated with increased thromboembolic (TE) complications, but concerns remain about the risk of symptomatic TE events, particularly when less aggressive chemical prophylaxis methods such as aspirin alone are chosen. Questions/purposes: We determined whether the rate of symptomatic TE events differed among patients given intraoperative TXA when three different postoperative prophylactic regimens were used after primary THA and TKA. Methods: We retrospectively reviewed 2046 patients who underwent primary THA or TKA and received TXA from 2007 to 2009. The three chemical regimens included aspirin alone, warfarin (target international normalized ratio, 1.8-2.2), and dalteparin. Primary outcome measures were venous TE events, including symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), and arterioocclusive events, including myocardial infarction and cerebrovascular accident. Patients judged to be at high risk for TE due to recent cardiac stent placement or strong personal/family history of TE disease were excluded. Results: For aspirin, warfarin, and dalteparin, the rates of symptomatic DVT (0.35%, 0.15%, and 0.52%, respectively) and nonfatal PE were similar (0.17%, 0.43%, and 0.26%, respectively). There were no fatal PE. Among the three groups, we found no difference in the rates of symptomatic DVT or PE with or without stratification by ASA score. Conclusions: A low complication rate was seen when using TXA as a blood conservation modality during primary THA and TKA with less aggressive thromboprophylactic regimens such as aspirin alone and dose-adjusted warfarin. Level of Evidence: Level III, therapeutic study. See the Instructions for Authors for a complete description of levels of evidence.
AB - Background: The use of antifibrinolytic medications in hip and knee arthroplasty reduces intraoperative blood loss and decreases transfusion rates postoperatively. Tranexamic acid (TXA) specifically has not been associated with increased thromboembolic (TE) complications, but concerns remain about the risk of symptomatic TE events, particularly when less aggressive chemical prophylaxis methods such as aspirin alone are chosen. Questions/purposes: We determined whether the rate of symptomatic TE events differed among patients given intraoperative TXA when three different postoperative prophylactic regimens were used after primary THA and TKA. Methods: We retrospectively reviewed 2046 patients who underwent primary THA or TKA and received TXA from 2007 to 2009. The three chemical regimens included aspirin alone, warfarin (target international normalized ratio, 1.8-2.2), and dalteparin. Primary outcome measures were venous TE events, including symptomatic deep vein thrombosis (DVT) and pulmonary embolism (PE), and arterioocclusive events, including myocardial infarction and cerebrovascular accident. Patients judged to be at high risk for TE due to recent cardiac stent placement or strong personal/family history of TE disease were excluded. Results: For aspirin, warfarin, and dalteparin, the rates of symptomatic DVT (0.35%, 0.15%, and 0.52%, respectively) and nonfatal PE were similar (0.17%, 0.43%, and 0.26%, respectively). There were no fatal PE. Among the three groups, we found no difference in the rates of symptomatic DVT or PE with or without stratification by ASA score. Conclusions: A low complication rate was seen when using TXA as a blood conservation modality during primary THA and TKA with less aggressive thromboprophylactic regimens such as aspirin alone and dose-adjusted warfarin. Level of Evidence: Level III, therapeutic study. See the Instructions for Authors for a complete description of levels of evidence.
UR - http://www.scopus.com/inward/record.url?scp=84871621159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871621159&partnerID=8YFLogxK
U2 - 10.1007/s11999-012-2488-z
DO - 10.1007/s11999-012-2488-z
M3 - Article
C2 - 22814857
AN - SCOPUS:84871621159
SN - 0009-921X
VL - 471
SP - 150
EP - 154
JO - Clinical orthopaedics and related research
JF - Clinical orthopaedics and related research
IS - 1
ER -